SLXN
NASDAQ HealthcareSilexion Therapeutics Corp - Ordinary Shares
Biotechnology
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
๐ Market Data
| Price | $0.44 |
|---|---|
| Volume | 26,834,702 |
| Market Cap | 2.42M |
| Beta | -0.360 |
| RSI (14-Day) | 52.9 |
| 200-Day MA | $10.37 |
| 50-Day MA | $1.22 |
| 52-Week High | $42.60 |
| 52-Week Low | $0.32 |
| Forward P/E | -0.68 |
| Price / Book | 54.44 |
๐ฏ Investment Strategy Scores
SLXN scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (99/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Moon Shot (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find SLXN in your text
Paste any article, transcript, or post โ the tool will extract SLXN and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.